Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
about
Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53Small cell lung cancer (SCLC): no treatment advances in recent yearsResistance and gain-of-resistance phenotypes in cancers harboring wild-type p53Small molecule compounds targeting the p53 pathway: are we finally making progress?Inhibition of nutlin-resistant HDM2 mutants by stapled peptidesHalogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactionsThe rebel angel: mutant p53 as the driving oncogene in breast cancer.The role of p53 in cancer drug resistance and targeted chemotherapyA step closer toward therapies for p63-related disordersAPR-246/PRIMA-1(MET) rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutationsp53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening systemSmall-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathologyRescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation.Degradation of mutant p53H175 protein by Zn(II) through autophagy.Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.Phytochemicals Approach for Developing Cancer Immunotherapeutics.Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons.Senescent cells and their secretory phenotype as targets for cancer therapy.Ceramide modulates pre-mRNA splicing to restore the expression of wild-type tumor suppressor p53 in deletion-mutant cancer cells.p53 Family and Cellular Stress Responses in Cancer.p53 Stabilization induces cell growth inhibition and affects IGF2 pathway in response to radiotherapy in adrenocortical cancer cellsTargeting p53 by small molecules in hematological malignancies.Mechanism of initiation of aggregation of p53 revealed by Φ-value analysisSmall molecule BMH-compounds that inhibit RNA polymerase I and cause nucleolar stress.Technical phosphoproteomic and bioinformatic tools useful in cancer research.TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in Non-Small Cell Lung Cancer treatment.Chaperoning of mutant p53 protein by wild-type p53 protein causes hypoxic tumor regression.Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils.Bioinformatics and variability in drug response: a protein structural perspective.N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: potential for cancer therapy.Mutant p53: one name, many proteins.Selective killing of p53-deficient cancer cells by SP600125.Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage.Molecular basis for the tissue specificity of β-catenin oncogenesis.Clinical proteomics and OMICS clues useful in translational medicine researchPRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms.PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation.Periostin cooperates with mutant p53 to mediate invasion through the induction of STAT1 signaling in the esophageal tumor microenvironment.Reactivation of mutant p53 by capsaicin, the major constituent of peppers
P2860
Q24628577-F6231EDB-63E6-47DC-8970-77F1FA27D757Q26767020-E343C34D-E7E0-4AB7-B453-E7B4A2603691Q27006998-691005BF-5FAC-4B87-A6DE-8CBEB167AE05Q27027835-D3534CC2-7211-43F2-9BDE-65274C773770Q27301404-630A8C29-58B6-4478-A4DD-40062A252BB0Q27678152-640ECFA5-2C07-450F-8E34-A818462D9ABAQ27679121-9362D83D-D9E2-4430-8081-4B92A620E61CQ27686765-33BFF43B-D5C2-40CE-A974-76C1D987CB41Q28072553-F5475852-83E5-4921-8CED-E62650D60A0AQ28243496-03ADC014-7F0B-4686-9018-681B5C99C097Q28284341-14130272-F10A-4C85-A73D-F615C0FD24CAQ28478414-A4C7B1C4-59A4-43EA-8562-66915A524F74Q30421643-54EED405-D231-4F32-B724-C3D26F9352DBQ33627342-44C5A7ED-71A8-4F72-A0F0-87D2CA35FE21Q33709136-1F6A211B-64C9-4535-B687-B5003577D471Q33733991-65A4C0D7-D322-42E6-82B8-4184E54024AFQ33809573-3F5C68B4-A95C-4574-AAE8-8BB420EB82FCQ34096644-749726B3-84E8-4B95-B0A2-6BFFB061C5BDQ34206082-98ABC9AA-1D87-4F4C-942A-27D3FDE6C852Q34302149-3B2161BD-B917-4FC7-8127-1A0D393FF1D7Q34377287-6F1E24D6-C8A5-4BA4-8DDC-0D6425E2462EQ34428159-96A0B851-711E-444E-8A1E-ED19E2C79C95Q34636996-3A5C2D16-A8A6-466A-86A0-2CDDB2D0E346Q35134797-55529CD1-0391-4437-A2F5-94C71810906BQ35296557-F5FF6FEC-0DB7-4E5C-9304-9DE77443FAFFQ35373413-EF254D0B-B67C-4C3E-9929-37658E0FDA42Q35646576-B1951401-3893-4CDC-BCEA-C48BB60455DBQ35710194-3DE0B4D8-2448-4152-8420-196C2AE1E06AQ35795073-DF32C3BF-8758-4A05-9BD9-7F38877B989BQ36009999-3241D552-B657-45EE-B283-ACDFE1BB03CCQ36055168-4189B16B-30C8-473A-9863-459A420AFC70Q36070574-577C8A28-6843-40EB-81D0-0AFC2B2FB95FQ36238666-7BF81A53-CFF9-4F69-8B85-B29F9D3F6A04Q36413546-4FA0F06C-DF7C-4DC4-888A-F28F349C45EAQ36501328-270D08A6-145E-4844-8E7A-146724084420Q36507644-9856F2C8-6338-4B0F-AB0A-A88F7F378F68Q36546764-A5A11134-DD2D-48A2-98C2-39E3148451B4Q36794233-EFC6E133-955A-44D6-920C-7B827C2DECE1Q37137255-CA7206EA-9190-4528-B0B3-654A4DA3AFFAQ37233582-E2919ECF-F0AA-4DF0-A303-AE63A9BD8ED0
P2860
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
@ast
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
@en
type
label
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
@ast
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
@en
prefLabel
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
@ast
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
@en
P356
P1433
P1476
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2010.188
P407
P577
2010-05-24T00:00:00Z
P6179
1050981473